236 related articles for article (PubMed ID: 33045493)
21. [Effects of extended aromatase inhibitors in women with hormone-dependent breast cancer who have already received five years of adjuvant hormone therapy: A systematic review and meta-analysis].
Trenou KC; Mésidor M; Diorio C; Eslami A; Talbot D
Bull Cancer; 2024 Apr; 111(4):356-362. PubMed ID: 38453587
[TBL] [Abstract][Full Text] [Related]
22. Aromatase inhibitors and the risk of colorectal cancer in postmenopausal women with breast cancer.
Khosrow-Khavar F; Yin H; Barkun A; Bouganim N; Azoulay L
Ann Oncol; 2018 Mar; 29(3):744-748. PubMed ID: 29293897
[TBL] [Abstract][Full Text] [Related]
23. Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer.
Dent SF; Gaspo R; Kissner M; Pritchard KI
Breast Cancer Res Treat; 2011 Apr; 126(2):295-310. PubMed ID: 21249443
[TBL] [Abstract][Full Text] [Related]
24. Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: Putting safety issues into perspective.
Conte P; Frassoldati A
Breast J; 2007; 13(1):28-35. PubMed ID: 17214790
[TBL] [Abstract][Full Text] [Related]
25. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
[TBL] [Abstract][Full Text] [Related]
26. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.
Howell A; Cuzick J; Baum M; Buzdar A; Dowsett M; Forbes JF; Hoctin-Boes G; Houghton J; Locker GY; Tobias JS;
Lancet; 2005 Jan 1-7; 365(9453):60-2. PubMed ID: 15639680
[TBL] [Abstract][Full Text] [Related]
27. Treatment strategies that effectively reduce early recurrence risk in postmenopausal women with endocrine-sensitive breast cancer: AIs upfront vs. switching.
Paepke S; Jacobs VR; Ohlinger R; Warm M; Kümmel S; Thomas A; Harbeck N; Kiechle-Bahat M
J Cancer Res Clin Oncol; 2007 Dec; 133(12):905-16. PubMed ID: 17805570
[TBL] [Abstract][Full Text] [Related]
28. Incidence of menopausal symptoms in postmenopausal breast cancer patients treated with aromatase inhibitors.
Hong D; Bi L; Zhou J; Tong Y; Zhao Q; Chen J; Lu X
Oncotarget; 2017 Jun; 8(25):40558-40567. PubMed ID: 28489562
[TBL] [Abstract][Full Text] [Related]
29. Safety of aromatase inhibitor therapy in breast cancer.
Lintermans A; Neven P
Expert Opin Drug Saf; 2015 Aug; 14(8):1201-11. PubMed ID: 26059833
[TBL] [Abstract][Full Text] [Related]
30. Aromatase inhibitors and mood disturbances.
Rocha-Cadman X; Massie MJ; Du Hamel K
Palliat Support Care; 2012 Sep; 10(3):225-7. PubMed ID: 22677000
[TBL] [Abstract][Full Text] [Related]
31. Adjuvant endocrine therapy side-effects among postmenopausal breast cancer patients in Malaysia.
Choo SB; Saifulbahri A; Zullkifli SN; Fadzil ML; Redzuan AM; Abdullah N; Bustamam RSA; Ahmad HZ; Shah NM
Climacteric; 2019 Apr; 22(2):175-181. PubMed ID: 30556740
[TBL] [Abstract][Full Text] [Related]
32. Aromatase inhibitor-related musculoskeletal symptoms: is preventing osteoporosis the key to eliminating these symptoms?
Muslimani AA; Spiro TP; Chaudhry AA; Taylor HC; Jaiyesimi I; Daw HA
Clin Breast Cancer; 2009 Feb; 9(1):34-8. PubMed ID: 19299238
[TBL] [Abstract][Full Text] [Related]
33. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
Romero SA; Young K; Hickey M; Su HI
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD007245. PubMed ID: 33348436
[TBL] [Abstract][Full Text] [Related]
34. Aromatase inhibitors as adjuvant therapy for postmenopausal patients with early stage breast cancer.
Kudachadkar R; O'Regan RM
CA Cancer J Clin; 2005; 55(3):145-63. PubMed ID: 15890638
[TBL] [Abstract][Full Text] [Related]
35. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
[TBL] [Abstract][Full Text] [Related]
36. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.
Jakesz R; Greil R; Gnant M; Schmid M; Kwasny W; Kubista E; Mlineritsch B; Tausch C; Stierer M; Hofbauer F; Renner K; Dadak C; Rücklinger E; Samonigg H;
J Natl Cancer Inst; 2007 Dec; 99(24):1845-53. PubMed ID: 18073378
[TBL] [Abstract][Full Text] [Related]
37. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
Baum M; Buzdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T;
Cancer; 2003 Nov; 98(9):1802-10. PubMed ID: 14584060
[TBL] [Abstract][Full Text] [Related]
38. Osteoporotic Fractures of the Spine, Hip, and Other Locations after Adjuvant Endocrine Therapy with Aromatase Inhibitors in Breast Cancer Patients: a Meta-analysis.
Lee YK; Lee EG; Kim HY; Lee Y; Lee SM; Suh DC; Yoo JI; Lee S
J Korean Med Sci; 2020 Nov; 35(46):e403. PubMed ID: 33258332
[TBL] [Abstract][Full Text] [Related]
39. Aromatase inhibitor-associated arthralgia syndrome.
Burstein HJ
Breast; 2007 Jun; 16(3):223-34. PubMed ID: 17368903
[TBL] [Abstract][Full Text] [Related]
40. Optimal duration of endocrine therapy with extended aromatase inhibitors for postmenopausal patients with hormone receptor-positive breast cancer: a meta-analysis.
Chen J; Zhang X; Lu Y; Zhang T; Ouyang Z; Sun Q
Breast Cancer; 2021 May; 28(3):630-643. PubMed ID: 33387283
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
